Abiopharma

🔍 Schwab Charles R. (Executive)

Company: Local Bounti Corporation/DE (LOCL)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 0 shares of Convertible Note at $2.5 per share (Derivative)
  Date: 2026-03-13 | Code: P | Expires: 2031-03-13 | Exercise: 2026-03-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2
• Acquired 5,500,000 shares of Common Stock Purchase Warrant at $0.125 per share (Derivative)
  Date: 2026-03-13 | Code: P | Expires: 2036-03-13 | Exercise: 2026-03-13 | equity_swap_involved: 0 | shares_owned_after: 5,500,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2

Footnotes:

• F1: On March 13, 2026, U.S. Bounti, LLC ("U.S. Bounti") and Local Bounti Corporation (the "Issuer") entered into an agreement (the "Purchase Agreement") under which U.S. Bounti purchased from the Issuer, for a combined purchase price of $15 million, (i) a convertible note with an initial principal balance of $15 million (the "Note") and (ii) a warrant (the "Warrant") pursuant to which U.S. Bounti has the right to purchase and acquire 5,500,000 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). Pursuant to the Purchase Agreement, U.S. Bounti will not have the right to receive, upon conversion of the Note or exercise of the Warrant, any shares of Common Stock if the issuance of such shares would exceed 222,241. Such limitation will not apply after stockholder approval is obtained and deemed effective, as required by the New York Stock Exchange. The Issuer is required to seek such stockholder approval at a stockholder meeting no later than June 30, 2026.
• F2: Securities held by U.S. Bounti, LLC.